Your browser is no longer supported. Please, upgrade your browser.
Settings
CLRB Cellectar Biosciences, Inc. daily Stock Chart
CLRB [NASD]
Cellectar Biosciences, Inc.
Index- P/E- EPS (ttm)-4.83 Insider Own0.60% Shs Outstand5.80M Perf Week-18.78%
Market Cap10.79M Forward P/E- EPS next Y-1.32 Insider Trans0.31% Shs Float5.15M Perf Month-20.51%
Income-15.60M PEG- EPS next Q-0.69 Inst Own6.90% Short Float3.17% Perf Quarter-4.12%
Sales- P/S- EPS this Y51.10% Inst Trans-3.84% Short Ratio0.31 Perf Half Y-18.78%
Book/sh1.69 P/B1.10 EPS next Y45.00% ROA-115.50% Target Price6.80 Perf Year-82.40%
Cash/sh1.81 P/C1.03 EPS next 5Y- ROE-169.60% 52W Range1.22 - 12.76 Perf YTD20.00%
Dividend- P/FCF- EPS past 5Y57.70% ROI- 52W High-85.42% Beta1.15
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low52.46% ATR0.26
Employees15 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)38.06 Volatility13.62% 10.71%
OptionableNo Debt/Eq0.00 EPS Q/Q63.30% Profit Margin- Rel Volume0.77 Prev Close2.00
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume531.62K Price1.86
Recom1.70 SMA20-19.45% SMA50-20.63% SMA200-20.89% Volume404,623 Change-7.00%
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
May-20-19 04:10PM  Cellectar Biosciences Announces Closing of $10.0 Million Financing GlobeNewswire -7.00%
May-18-19 07:15AM  5 Biotech Stocks to Watch in the Second Half of 2019 ETF Trends
May-16-19 08:52AM  Cellectar Biosciences Announces $10.0 Million Financing GlobeNewswire -22.70%
May-15-19 08:30AM  CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma GlobeNewswire +23.68%
May-13-19 08:00AM  Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma GlobeNewswire
May-06-19 08:00AM  Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update GlobeNewswire
May-02-19 02:18PM  5 Biotech Stocks With Near-Term Catalysts Ahead Benzinga
Apr-29-19 10:20AM  Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Apr-10-19 01:40PM  5 Oncology Companies That Are Set to Run GuruFocus.com
Mar-19-19 08:30AM  FDA Grants Exemption to Import Alert for Cellectars CLR 131 in Pediatric and Adolescent Patients GlobeNewswire
Feb-26-19 08:30AM  Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update GlobeNewswire
Feb-25-19 08:30AM  Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 GlobeNewswire
Feb-05-19 08:30AM  Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference GlobeNewswire
Jan-23-19 08:00AM  Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets Fifteenth Annual Investor Conference GlobeNewswire -5.83%
Jan-22-19 02:15PM  What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)? Simply Wall St.
Jan-07-19 08:30AM  Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire +8.14%
Jan-03-19 08:30AM  Cellectar Biosciences to Present at the Biotech Showcase GlobeNewswire
Dec-11-18 08:30AM  Cellectar Granted Japanese Patent for CLR 131 GlobeNewswire
Dec-04-18 08:30AM  Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire
Nov-21-18 02:53PM  Analysts Take Action on Health Care Stocks GuruFocus.com +8.84%
Nov-13-18 08:30AM  Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-12-18 08:30AM  Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies GlobeNewswire
Oct-02-18 08:00AM  Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma GlobeNewswire +12.16%
Sep-27-18 08:30AM  Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire -8.36%
08:00AM  Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences ACCESSWIRE
Sep-25-18 08:30AM  Cellectars CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma GlobeNewswire
Sep-24-18 08:00AM  Cellectar Biosciences Provides an Update on the FDA Import Alert GlobeNewswire
Sep-17-18 08:43AM  Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer MarketWatch
08:30AM  FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences CLR 131 for the Treatment of Osteosarcoma GlobeNewswire
Aug-29-18 08:30AM  Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-20-18 08:30AM  Fractionated Dosing Improves Tolerability and Safety of Cellectars CLR 131 in R/R Multiple Myeloma Patients GlobeNewswire -6.67%
Aug-13-18 09:25AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:00AM  Cellectars CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewings Sarcoma GlobeNewswire
Aug-10-18 08:00AM  Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update GlobeNewswire -8.65%
Aug-01-18 08:30AM  Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate GlobeNewswire
Jul-31-18 04:05PM  Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option GlobeNewswire -7.27%
Jul-27-18 08:30AM  Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering GlobeNewswire -37.15%
Jul-18-18 08:20AM  Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences ACCESSWIRE -7.86%
08:00AM  Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients GlobeNewswire
Jul-17-18 01:25PM  Cellectar Biosciences shares surge 15% on results of one cancer patient in mid-stage trial MarketWatch
12:04PM  Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug Benzinga
08:00AM  Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study GlobeNewswire
Jul-13-18 04:05PM  Cellectar Announces 1-for-10 Reverse Stock Split GlobeNewswire
Jul-09-18 08:00AM  Cellectars CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewings Sarcoma GlobeNewswire +22.02%
Jun-28-18 08:00AM  Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial GlobeNewswire -5.09%
Jun-07-18 08:30AM  Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 GlobeNewswire
Jun-06-18 08:00AM  FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences CLR 131 for the Treatment of Rhabdomyosarcoma GlobeNewswire +10.88%
May-11-18 08:00AM  Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results GlobeNewswire
May-09-18 02:28PM  Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma GlobeNewswire +6.31%
May-04-18 07:30AM  Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA ACCESSWIRE
May-02-18 08:00AM  Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma GlobeNewswire
Apr-17-18 08:00AM  Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma GlobeNewswire
Apr-16-18 08:05AM  Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells GlobeNewswire -5.60%
08:00AM  Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectars CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting GlobeNewswire
Apr-04-18 08:00AM  Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer GlobeNewswire
Apr-03-18 08:00AM  Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma GlobeNewswire
Mar-27-18 08:00AM  Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles GlobeNewswire
Mar-22-18 06:30AM  Cellectar BioSciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 04:10PM  Cellectar Reports 2017 Financial Results and Provides a Corporate Update GlobeNewswire
Mar-19-18 08:45AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:05AM  Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma GlobeNewswire
08:00AM  Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018 GlobeNewswire
Mar-15-18 08:00AM  Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131 GlobeNewswire
Mar-08-18 07:30AM  Wired News Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology ACCESSWIRE
Mar-06-18 08:00AM  Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology GlobeNewswire
Mar-05-18 08:00AM  Cellectar Biosciences to Present at Upcoming March Conferences GlobeNewswire
Feb-08-18 08:15AM  Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-07-18 08:15AM  Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma GlobeNewswire
Jan-29-18 10:00AM  2 Biotech Stocks to Watch This Quarter ACCESSWIRE +7.32%
08:00AM  Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers GlobeNewswire
Jan-23-18 05:23PM  How Much is Cellectar Biosciences Incs (NASDAQ:CLRB) CEO Getting Paid? Simply Wall St.
Jan-22-18 08:30AM  Cellectar Biosciences to Participate at Noble Capital Markets Fourteenth Annual Investor Conference GlobeNewswire
Jan-04-18 08:00AM  Cellectar Biosciences to Participate at Biotech Showcase 2018 GlobeNewswire
Dec-14-17 08:43AM  Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers GlobeNewswire -5.88%
Dec-08-17 12:33PM  Is Cellectar Biosciences Inc (CLRB) Thriving Or Barely Surviving In The Healthcare Sector? Simply Wall St.
Dec-06-17 08:00AM  Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 GlobeNewswire
Nov-20-17 08:30AM  Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event GlobeNewswire
Nov-10-17 04:52PM  Edited Transcript of CLRB earnings conference call or presentation 10-Nov-17 1:00pm GMT Thomson Reuters StreetEvents -6.71%
Nov-09-17 04:01PM  Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance GlobeNewswire +5.13%
Nov-07-17 08:30AM  Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma GlobeNewswire
Nov-02-17 08:30AM  Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance GlobeNewswire
Oct-30-17 08:30AM  New Preclinical Data Suggest That Cellectar Biosciences PDC Platform Provides Enhanced Outcomes in Combination with External Radiation GlobeNewswire
Oct-24-17 08:30AM  Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma GlobeNewswire
Oct-17-17 08:30AM  Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors GlobeNewswire
Oct-12-17 11:00AM  Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering GlobeNewswire -6.25%
Oct-10-17 01:30PM  Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market GlobeNewswire
07:30AM  Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates GlobeNewswire
Sep-29-17 08:30AM  Cellectar Biosciences to Present at The MicroCap Conference GlobeNewswire
Sep-27-17 08:30AM  Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 GlobeNewswire
Sep-21-17 08:30AM  Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates GlobeNewswire
Sep-20-17 08:30AM  Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-18-17 08:30AM  Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer GlobeNewswire
Sep-06-17 08:30AM  Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference GlobeNewswire
Aug-22-17 08:30AM  Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window GlobeNewswire +20.95%
Aug-15-17 03:10PM  Edited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT Thomson Reuters StreetEvents +5.44%
Aug-14-17 04:45PM  Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance GlobeNewswire
Aug-08-17 08:30AM  Cellectar Biosciences CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients GlobeNewswire +11.39%
Aug-03-17 08:30AM  Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance GlobeNewswire
Aug-01-17 08:30AM  Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors GlobeNewswire
Jun-15-17 07:17AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longcor JarrodChief Business OfficerFeb 28Buy2.001002007,300Mar 01 04:20 PM
CARUSO JAMES VPresident and CEONov 30Buy2.281,0002,28222,354Nov 30 06:23 PM
HILL STEPHEN ADirectorNov 29Sale2.219922,1920Nov 30 06:19 PM
Longcor JarrodChief Business OfficerAug 16Buy2.715001,3557,200Aug 17 06:14 PM